Good Products, a provider of Enterprise Content Management (ECM) solutions for the pharmaceutical, biotechnology and medical device industries, and Adlib Software, a producer of server-based document conversion, recognition and publishing software, announced an OEM partnership.
Good Products and Adlib Software Partner to Facilitate Pharmaceutical
Regulatory Submissions
(24 September, 2008) Good Products, a leading provider of Enterprise Content Management (ECM) solutions for the pharmaceutical, biotechnology and medical device industries, and Adlib Software, a leading producer of server-based document conversion, recognition and publishing software, today announced an OEM partnership. This new partnership has been formed to facilitate regulatory submissions in the pharmaceutical industry and will see the integration of Good Products' electronic document management system (eDMS) g-docs with Adlib Software's Express Server centralized PDF rendering tool.
The collaboration between the two industry-leading scientific software providers addresses the need from the pharmaceutical industry for streamlined and compliant regulatory document management. Using the new integrated system, pharmaceutical organizations will be able to store, manage and track regulatory documents and create high quality regulatory submission-ready PDFs with bookmarks and hyperlinks.
g-docs from Good Products offers life sciences organizations an effective, easy-to-use way of managing their documents including tracking document version history, managing approvals, monitoring and recording changes in an audit log. Additionally, g-docs incorporates CoSign, a digital signature solution that allows an individual to digitally sign a document as if they were using ink. CoSign digital signatures have now been upheld in the US court, and are deemed to pass the 'non- repudiation' test as well as being compliant with the FDA's 21 CFR part 11 Guidance. g-docs uses Adlib Express Server to automatically convert different document formats including Microsoft Office, scanned images, engineering drawings and web and image formats to PDF while meeting the requirements of international regulatory bodies, including the FDA. g-docs also uses Adlib to automatically maintain audit, version, reference and distribution tables within the rendered documents, massively saving time and at the push of a button.
Peter Duff, president and CEO, Adlib Software, comments: "Our partnership with Good Products complements the ability to provide compliant document conversion systems to the pharmaceutical industry. The integration of g-docs and Express Server accelerates regulatory submissions and enables organizations to manage documents in a compliant way across the whole lifecycle, from creation to regulatory submission."
"With the increasing standardization of regulatory submissions in an electronic format, and the need to simplify the User experience, both Adlib Software and Good Products recognize the importance of maintaining the consistency and accuracy of electronic documentation from creation to submission," adds Keith Williams, CEO, Good Products. "We are now looking to work together to develop further enhancements and functionality, enabling deeper integration of Good Products and Adlib Software solutions."
For further information on the Good Products portfolio of document management systems, please visit www.goodproductsEU.com or email info@goodproductsEU.com.
For further information on Adlib Software, please visit www.adlibsoftware.com or email info@adlibsoftware.com.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.